Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Long-Term Deferred Tax (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Long-Term Deferred Tax for 6 consecutive years, with $38.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Long-Term Deferred Tax rose 24.74% year-over-year to $38.4 million, compared with a TTM value of $38.4 million through Sep 2025, up 24.74%, and an annual FY2024 reading of $33.4 million, up 9.47% over the prior year.
  • Long-Term Deferred Tax was $38.4 million for Q3 2025 at Cytek Biosciences, up from $35.8 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $38.4 million in Q3 2025 and bottomed at $7.4 million in Q2 2021.
  • Average Long-Term Deferred Tax over 5 years is $23.3 million, with a median of $25.2 million recorded in 2023.
  • The sharpest move saw Long-Term Deferred Tax soared 125.74% in 2023, then rose 3.06% in 2025.
  • Year by year, Long-Term Deferred Tax stood at $9.2 million in 2021, then soared by 123.03% to $20.5 million in 2022, then surged by 49.02% to $30.5 million in 2023, then increased by 9.47% to $33.4 million in 2024, then grew by 15.04% to $38.4 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for CTKB at $38.4 million in Q3 2025, $35.8 million in Q2 2025, and $33.7 million in Q1 2025.